Dr. Lovly is a physician-scientist with a special interest in thoracic malignancies.

She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She completed her graduate students in the laboratory of Helena Piwnica-Worms, PhD. 

She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her medical oncology fellowship, she completed research fellowship in the laboratory of William Pao, MD, PhD. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow.

D. Lovly started on faculty at Vanderbilt in July 2013 as an Assistant Professor of Medicine and Cancer Biology in July 2013. Dr. Lovly's clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer.

She has received independent grant funding from the Damon Runyon Foundation, the V Foundation, LUNGevity, Uniting Against Lung Cancer, AACR, and the Conquer Cancer Foundation of the American Society of Clinical Oncology. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR).

Dr. Lovly is also the co-Editor-in Chief for the website, a Vanderbilt initiated, freely available website which aims to provide health care practitioners, patient, and advocates with up-to-date information regarding genetically informed cancer medicine.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L (2016) Lung Cancer : 29-34
    › Primary publication · 26775593 (PubMed) · PMC4874190 (PubMed Central)
  2. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J (2016) Cancer Res 76(2): 305-18
    › Primary publication · 26744526 (PubMed) · PMC4715957 (PubMed Central)
  3. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN (2016) J Clin Oncol 34(2): 123-9
    › Primary publication · 26438117 (PubMed) · PMC5070549 (PubMed Central)
  4. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Iams WT, Lovly CM (2015) Clin Cancer Res 21(19): 4270-7
    › Primary publication · 26429980 (PubMed) · PMC4593065 (PubMed Central)
  5. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Iams WT, Lovly CM (2015) Cancer J 21(5): 378-82
    › Primary publication · 26389762 (PubMed) · PMC5242382 (PubMed Central)
  6. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG (2015) Nat Med 21(9): 1038-47
    › Primary publication · 26301689 (PubMed) · PMC4734742 (PubMed Central)
  7. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM (2015) Cancer Discov 5(11): 1155-63
    › Primary publication · 26286086 (PubMed) · PMC4631701 (PubMed Central)
  8. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Ichihara E, Lovly CM (2015) Cancer Discov 5(7): 694-6
    › Primary publication · 26152920 (PubMed) · PMC4499857 (PubMed Central)
  9. Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Meador CB, Lovly CM (2015) Nat Med 21(7): 663-5
    › Primary publication · 26151324 (PubMed)
  10. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Lovly CM (2015) Am Soc Clin Oncol Educ Book : e165-73
    › Primary publication · 25993168 (PubMed) · PMC4734636 (PubMed Central)